Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19582798 | 1.00 | TAAR1 (0.45) | TAAR1HTR2AALOX5MEN1KMT2A | |
| SCHEMBL17593201 | 1.00 | TAAR1 (0.45) | TAAR1HTR2AALOX5MEN1KMT2A | |
| SCHEMBL8804536 | 0.79 | TAAR1 (0.45) | TAAR1ALOX5MEN1KMT2ASLC6A2 | |
| SCHEMBL8803172 | 0.79 | DRD4 (0.50) | TAAR1ALOX5MEN1KMT2ASLC6A2 | |
| SCHEMBL14524332 | 0.79 | ALOX5 (0.46) | ALOX5MEN1KMT2ASLC6A2SLC6A4 | |
| SCHEMBL8804326 | 0.79 | CYP1A2 (0.45) | TAAR1ALOX5MEN1KMT2ASLC6A2 | |
| SCHEMBL8804583 | 0.79 | DRD4 (0.51) | TAAR1ALOX5MEN1KMT2ASLC6A2 | |
| SCHEMBL19321713 | 0.79 | CYP1A2 (0.45) | TAAR1ALOX5MEN1KMT2ASLC6A2 | |
| SCHEMBL24137898 | 0.78 | MEN1 (0.62) | TAAR1MEN1KMT2ASLC6A2SLC6A4 | |
| SCHEMBL11477197 | 0.78 | MAPT (0.43) | TAAR1HTR2AMAPTSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2173740-A1 | HEME-OXYGENASE INHIBITORS AND USE OF THE SAME IN THE TREATMENT OF CANCER AND DISEASES OF THE CENTRAL NERVOUS SYSTEM | Osta Biotechnologies (CA) | 2010-04-14 | — | — | EP | claimed |
| WO-2008151437-A1 | HEME-OXYGENASE INHIBITORS AND USE OF THE SAME IN THE TREATMENT OF CANCER AND DISEASES OF THE CENTRAL NERVOUS SYSTEM | OSTA BIOTECHNOLOGIES (CA) | 2008-12-18 | — | — | WO | claimed |
| EP-3191453-B1 | PHENYL-(AZA)CYCLOALKYL CARBOXYLIC ACID GPR120 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-23 | — | — | EP | disclosed |
| EP-3191453-B1 | PHENYL-(AZA)CYCLOALKYL CARBOXYLIC ACID GPR120 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-23 | — | — | EP | disclosed |
| US-10336684-B2 | Phenyl-(aza)cycloalkyl carboxylic acid GPR120 modulators | BRISTOL=MYERS SQUIBB COMPANY (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180319737-A1 | PHENYL-(AZA)CYCLOALKYL CARBOXYLIC ACID GPR120 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-11-08 | — | — | US | disclosed |
| US-20170327457-A1 | PHENYL-(AZA)CYCLOALKYL CARBOXYLIC ACID GPR120 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-16 | — | — | US | disclosed |
| EP-3191453-A1 | PHENYL-(AZA)CYCLOALKYL CARBOXYLIC ACID GPR120 MODULATORS | Bristol-Myers Squibb Company (US) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016040225-A1 | PHENYL-(AZA)CYCLOALKYL CARBOXYLIC ACID GPR120 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-17 | — | — | WO | disclosed |
| US-20140155445-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2014-06-05 | — | — | US | disclosed |
| US-20140155445-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2014-06-05 | — | — | US | disclosed |
| US-7943650-B2 | Methods of treating cancer with imidazolyl compounds | OSTA BIOTECHNOLOGIES (CA) | 2011-05-17 | — | — | US | disclosed |
| US-7943650-B2 | Methods of treating cancer with imidazolyl compounds | OSTA BIOTECHNOLOGIES (CA) | 2011-05-17 | — | — | US | disclosed |
| US-7943650-B2 | Methods of treating cancer with imidazolyl compounds | OSTA BIOTECHNOLOGIES (CA) | 2011-05-17 | — | — | US | disclosed |
| EP-2173740-A1 | HEME-OXYGENASE INHIBITORS AND USE OF THE SAME IN THE TREATMENT OF CANCER AND DISEASES OF THE CENTRAL NERVOUS SYSTEM | Osta Biotechnologies (CA) | 2010-04-14 | — | — | EP | disclosed |
| US-20090176831-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | OSTA BIOTECHNOLOGIES (CA) | 2009-07-09 | — | — | US | disclosed |
| US-20090176831-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | OSTA BIOTECHNOLOGIES (CA) | 2009-07-09 | — | — | US | disclosed |
| US-20090176831-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | OSTA BIOTECHNOLOGIES (CA) | 2009-07-09 | — | — | US | disclosed |
| WO-2008151437-A1 | HEME-OXYGENASE INHIBITORS AND USE OF THE SAME IN THE TREATMENT OF CANCER AND DISEASES OF THE CENTRAL NERVOUS SYSTEM | OSTA BIOTECHNOLOGIES (CA) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008151437-A1 | HEME-OXYGENASE INHIBITORS AND USE OF THE SAME IN THE TREATMENT OF CANCER AND DISEASES OF THE CENTRAL NERVOUS SYSTEM | OSTA BIOTECHNOLOGIES (CA) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155445-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | HMOX1, HMOX2, CYC1 | TAAR1 2422/4885HTR2A 1763/4885ALOX5 85/4885 |
| US-20170327457-A1 | PHENYL-(AZA)CYCLOALKYL CARBOXYLIC ACID GPR120 MODULATORS | GPR88, GPR55, GPR180 | TAAR1 150/4885HTR2A 285/4885ALOX5 900/4885 |
| US-20180319737-A1 | PHENYL-(AZA)CYCLOALKYL CARBOXYLIC ACID GPR120 MODULATORS | GPR88, GPR55, GPR180 | TAAR1 150/4885HTR2A 285/4885ALOX5 900/4885 |
| US-10336684-B2 | Phenyl-(aza)cycloalkyl carboxylic acid GPR120 modulators | GPR88, GPR55, GPR180 | TAAR1 150/4885HTR2A 285/4885ALOX5 900/4885 |
| US-20090176831-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | HMOX1, HMOX2, CYC1 | TAAR1 2611/4885HTR2A 1652/4885ALOX5 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.